Mohammedrashid Ibraheem, Aly Abouslima, Ahmed Ebrahim, Salma Ahmed, Sara E Elbahnasawy, Mohamed Hesham Gamal, Nada Ramadan, Manar Adel, Mahmoud M Elhady
{"title":"Drug-coated balloons in coronary disease: meta-analysis comparing sirolimus- and paclitaxel-coated technologies.","authors":"Mohammedrashid Ibraheem, Aly Abouslima, Ahmed Ebrahim, Salma Ahmed, Sara E Elbahnasawy, Mohamed Hesham Gamal, Nada Ramadan, Manar Adel, Mahmoud M Elhady","doi":"10.1186/s12872-026-06811-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Drug-coated balloons (DCBs) are a key alternative to drug-eluting stents for coronary artery interventions, offering the advantage of drug delivery without permanent implants. Both paclitaxel-coated balloons (PCBs) and sirolimus-coated balloons (SCBs) are valuable treatment options. This systematic review and meta-analysis compare the efficacy and safety of sirolimus-coated versus paclitaxel-coated balloon catheters in patients with coronary artery disease.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA guidelines, searching five databases. We exclusively included RCTs. Risk ratios (RR) and mean differences (MD) with 95% confidence intervals were calculated using fixed-effects or random-effects models, with sensitivity analysis performed in cases of heterogeneity.</p><p><strong>Results: </strong>Eight trials involving 1043 patients were included. The meta-analysis demonstrated no significant difference between SCB and PCB for late lumen loss (MD 0.06, 95% CI [-0.02 to 0.14]). Only two outcomes showed statistically significant differences favoring PCB: reducing late lumen enlargement (RR 0.66, 95% CI [0.49-0.87], P = 0.004) and, after sensitivity analysis, lowering binary restenosis rates in de novo lesions CONCLUSION: This meta-analysis shows SCB and PCB have similar safety and efficacy in coronary artery interventions, with no significant differences in most outcomes. However, PCB outperforms late lumen enlargement and binary restenosis rates in de novo lesions. Similar outcomes across sirolimus formulations indicate other factors influence success. Both balloon types appear safe and effective, though PCB may retain certain advantages in specific scenarios. Larger, longer-term studies are needed to establish the optimal drug-coated balloon strategy for different patient populations.</p><p><strong>Clinical trial number: </strong>not applicable.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"26 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13693106/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-026-06811-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aim: Drug-coated balloons (DCBs) are a key alternative to drug-eluting stents for coronary artery interventions, offering the advantage of drug delivery without permanent implants. Both paclitaxel-coated balloons (PCBs) and sirolimus-coated balloons (SCBs) are valuable treatment options. This systematic review and meta-analysis compare the efficacy and safety of sirolimus-coated versus paclitaxel-coated balloon catheters in patients with coronary artery disease.
Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines, searching five databases. We exclusively included RCTs. Risk ratios (RR) and mean differences (MD) with 95% confidence intervals were calculated using fixed-effects or random-effects models, with sensitivity analysis performed in cases of heterogeneity.
Results: Eight trials involving 1043 patients were included. The meta-analysis demonstrated no significant difference between SCB and PCB for late lumen loss (MD 0.06, 95% CI [-0.02 to 0.14]). Only two outcomes showed statistically significant differences favoring PCB: reducing late lumen enlargement (RR 0.66, 95% CI [0.49-0.87], P = 0.004) and, after sensitivity analysis, lowering binary restenosis rates in de novo lesions CONCLUSION: This meta-analysis shows SCB and PCB have similar safety and efficacy in coronary artery interventions, with no significant differences in most outcomes. However, PCB outperforms late lumen enlargement and binary restenosis rates in de novo lesions. Similar outcomes across sirolimus formulations indicate other factors influence success. Both balloon types appear safe and effective, though PCB may retain certain advantages in specific scenarios. Larger, longer-term studies are needed to establish the optimal drug-coated balloon strategy for different patient populations.
背景和目的:药物涂层气球(DCBs)是冠状动脉介入治疗中药物洗脱支架的重要替代方案,具有无需永久植入物即可给药的优点。紫杉醇包覆球囊(PCBs)和西罗莫司包覆球囊(SCBs)都是有价值的治疗选择。本系统综述和荟萃分析比较了西罗莫司包被球囊导管与紫杉醇包被球囊导管在冠心病患者中的疗效和安全性。方法:我们按照PRISMA指南进行了系统综述和meta分析,检索了5个数据库。我们只纳入了随机对照试验。使用固定效应或随机效应模型计算95%置信区间的风险比(RR)和平均差异(MD),并对异质性进行敏感性分析。结果:纳入8项试验,共1043例患者。荟萃分析显示,SCB和PCB在后期流明损失方面无显著差异(MD为0.06,95% CI[-0.02至0.14])。只有两项结果显示有统计学意义的差异:减少晚期管腔扩大(RR 0.66, 95% CI [0.49-0.87], P = 0.004),以及降低新发病变的二元再狭窄率。结论:本荟萃分析显示SCB和PCB在冠状动脉干预中具有相似的安全性和有效性,大多数结果无显著差异。然而,在新发病变中,PCB优于晚期管腔扩大和二元再狭窄率。所有西罗莫司制剂的类似结果表明,其他因素影响了成功。两种气球类型似乎都是安全有效的,尽管PCB在特定情况下可能保留某些优势。需要更大规模、更长期的研究来为不同的患者群体建立最佳的药物包被球囊策略。临床试验号:不适用。
期刊介绍:
BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.